Mochida Pharmaceutical (4534.T)

Executive Summary

Mochida Pharmaceutical Co., Ltd. is a Japanese pharmaceutical company with over 128 years of history, focusing on prescription drugs, consumer healthcare, and diagnostics. With a market capitalization of approximately $127.8 billion, it maintains a strong domestic presence and an integrated business model from R&D to commercialization. Its pipeline includes several late-stage assets, notably FYU-981 for hyperuricemia/gout, which has completed Phase 3 trials, and biosimilars like LBEC0101 for rheumatoid arthritis. The company also has expertise in metabolic and inflammatory diseases. While Mochida has a solid commercial foundation, its near-term growth prospects depend on regulatory approvals and strategic partnerships to expand internationally.

Upcoming Catalysts (preview)

• Q3 2026FYU-981 NDA Submission in Japan for Hyperuricemia70% success
• Q4 2026LBEC0101 (etanercept biosimilar) Approval Decision in Japan60% success
• TBDIcosapent (MND-2119) New Indication or Partnership50% success